Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» MK-0616
MK-0616
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Drugs.com
Merck
clinical trials
MK-0616
hypercholesterolemia
Flag link:
Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program
Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program
Fierce Biotech
Merck
PCSK9 inhibitors
clinical trials
cardiovascular disease
cholesterol
MK-0616
Flag link:
Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23
Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23
Endpoints
Merck
PAH
clinical trials
MK-0616
Flag link:
Can A New Cholesterol Drug Restore Merck’s Prominence In Heart Drugs?
Can A New Cholesterol Drug Restore Merck’s Prominence In Heart Drugs?
Forbes
Merck
cholesterol
PCSK9 inhibitors
MK-0616
Zocor
Flag link:
Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol
Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol
Endpoints
Merck
MK-0616
oral PCSK9 inhibitors
PCSK9 inhibitors
Flag link:
